Drugs / Luxdegalutamide
Luxdegalutamide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07174063 | Nov 2025 → Jan 2027 expected | metastatic prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07206056 | Oct 2025 → Nov 2029 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06991556 | Jul 2025 → Mar 2032 expected | metastatic prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07047118 | Jul 2025 → Jul 2027 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Luxdegalutamide | “A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer” NCT07174063 ↗ |
| Known as | JSB462 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07047118 ↗ |
| Known as | Luxdegalutamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314528 ↗ |
| Modality | Small molecule | — CHEMBL5314528 ↗ |
| Route | Oral | “JSB462 is administered from randomization, orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the...” NCT06991556 ↗ |